Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity.

× No keyword cloud information.

19 in total

1. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Authors: Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544

2. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors: W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

3. An indication of possible impending toxicity during moderately high dose methotrexate infusions.

Authors: J W Paxton; E J Stephens; H F Wood
Journal: Br J Clin Pharmacol Date: 1978-12 Impact factor: 4.335

4. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.

Authors: J D Borsi; D Schuler; P J Moe
Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333

5. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.

Authors: T S Goh; K Y Wong; B Lampkin; J O'Leary; D Gnarra
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

6. Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.

Authors: H J Cohen; N Jaffe
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

7. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

Authors: S B Howell; B B Chu; W E Wung; B M Metha; J Mendelsohn
Journal: J Clin Invest Date: 1981-04 Impact factor: 14.808

Review 8. Pharmacokinetics of anticancer drugs in children.

Authors: W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal: Clin Pharmacokinet Date: 1987-03 Impact factor: 6.447

9. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.

Authors: G E Umbach; G Spitzer; J A Ajani; V Hug; H Thames; F B Rudolph; B Drewinko
Journal: J Cancer Res Clin Oncol Date: 1986 Impact factor: 4.553

10. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.

Authors: M Luyckx; J L Cazin; C Brunet; P Gosselin; M C Demaille
Journal: Eur J Clin Pharmacol Date: 1985 Impact factor: 2.953